Stock ABBOTINDIA ABBOTT INDIA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Abbott India Limited NSE India S.E.

Equities

ABBOTINDIA

INE358A01014

Market Closed - NSE India S.E.
Other stock markets
 07:40:46 2024-04-29 am EDT 		5-day change 1st Jan Change
26,290 INR +1.52% Intraday chart for Abbott India Limited +0.62% +15.05%
Apr. 12 Abbott India Limited Appoints Murari Ranganathan as Commercial Director CI
Mar. 19 Abbott India's Managing Director Exits MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Strengths

  • Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
  • The group's activity appears highly profitable thanks to its outperforming net margins.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

Weaknesses

  • With an expected P/E ratio at 46.82 and 41.26 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
  • The company's "enterprise value to sales" ratio is among the highest in the world.
  • The company appears highly valued given the size of its balance sheet.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
ABBOTT INDIA LIMITED Stock Abbott India Limited
+15.05% 6.59B -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+25.85% 661B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.74% 566B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.64% 352B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.57% 332B
B-
ABBVIE INC. Stock AbbVie Inc.
+3.51% 283B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.43% 231B
B+
NOVARTIS AG Stock Novartis AG
+4.71% 200B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-9.53% 195B
A+
AMGEN INC. Stock Amgen Inc.
-4.55% 145B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
-
Potential Price Target
-
4m Target Price Revision
-
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
  1. Stock Market
  2. Equities
  3. ABBOTINDIA Stock
  4. ABBOTINDIA Stock
  5. Ratings Abbott India Limited